<DOC>
	<DOC>NCT02414594</DOC>
	<brief_summary>The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS APO(a)-LRx (ISIS 681257) given to healthy volunteer subjects.</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)</brief_title>
	<detailed_description />
	<criteria>Must have given written informed consent and be able to comply with all study requirements Healthy males or females aged 1865 inclusive and weighing ≥ 50 kg at the time of informed consent Females must be nonpregnant and nonlactating, and either surgically sterile or post menopausal Males must be surgically sterile, abstinent or using an acceptable contraceptive method BMI &lt; 35.0 kg/m2 Subjects must have Lp(a) ≥ 75 nanomoles/liter nmol/L (30 mg/dL) at Screening Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C or chronic hepatitis B Treatment with another Study Drug, biological agent, or device within onemonth of screening Regular use of alcohol within 6 months of Screening Use of concomitant drugs unless authorized by the Sponsor Medical Monitor Smoking &gt; 10 cigarettes a day Considered unsuitable for inclusion by the Principal Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>